Hepatitis B Virus Antibody in Blood Donors and the Occurrence of Non-A, Non-B Hepatitis in Transfusion Recipients

An Analysis of the Transfusion-Transmitted Viruses Study

  1. CLADD E. STEVENS, M.D.;
  2. RICHARD D. AACH, M.D.;
  3. F. BLAINE HOLLINGER, M.D.;
  4. JAMES W. MOSLEY, M.D.;
  5. WOLF SZMUNESS, M.D.;
  6. RICHARD KAHN, Ph.D.;
  7. JOCHEWED WERCH, M.D.; and
  8. VIRGINIA EDWARDS, B.S.
  1. New York, New York; Houston, Texas; Los Angeles, California; and St. Louis, Missouri

    Abstract

    Patients who received transfusions and nontransfused control patients were followed to assess the incidence and cause of post-transfusion hepatitis and to identify donor factors that might relate to risk of hepatitis. We evaluated as risk factors in donors the presence of antibody to hepatitis B virus compared with elevated alanine aminotransferase (ALT) level. Units of blood that were positive for antibody to hepatitis B core antigen (anti-HBc) were associated with a twofold to threefold greater risk of non-A, non-B hepatitis in the recipients than were units without anti-HBc. In the absence of specific serologic tests for non-A, non-B agents, screening

    Article and Author Information

    • ▸From the New York Blood Center, New York, New York; Washington University-Barnes Hospital, and the American Red Cross, Missouri-Illinois Region, St. Louis, Missouri; Baylor College of Medicine, Houston, Texas; and UCLA Center for Health Sciences, Los Angeles, California.

    • Dr. Szmuness has died.

    • The Transfusion-Transmitted Viruses Study Group consists of the following: Participating Institutions: the Lindsley F. Kimball Research Institute of The New York Blood Center, the New York Hospital, and the Hospital for Special Surgery, New York; Washington University School of Medicine-Barnes Hospital, and the Missouri-Illinois Regional Red Cross, St. Louis; Baylor College of Medicine, Ben Taub General Hospital, Jefferson Davis Hospital, and Methodist Hospital, Houston; and the UCLA Center for the Health Sciences, Los Angeles. Coordinating Center: University of Southern California School of Medicine, Los Angeles. Advisory Committee: Dr. Paul V. Holland, chairman; Dr. William H. Bancroft; Dr. Lawrence Shaw; and Dr. Hyman J. Zimmerman.

    • ▸Requests for reprints should be addressed to Cladd E. Stevens, M.D.; The Wolf Szmuness Laboratory of Epidemiology, The New York Blood Center, 310 East 67th Street; New York, NY 10021.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement